The Food and Drug Administration extended its review period for Portola Pharmaceuticals Inc.'s (Nasdaq: PTLA) AndexXa. The stock price plummeted $5.86 to close at $49.00.
FDA extends review period for Portola Pharmaceuticals
December 26, 2017 at 17:32 PM EST
